CD40 ligand expressing MSLN-CAR T
/ UTC Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 23, 2023
CD40 Ligand Expressing MSLN-CAR T Cell Therapy in MSLN Positive Advanced/Metastatic Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=30 | Recruiting | Sponsor: Chinese PLA General Hospital
CAR T-Cell Therapy • Metastases • New P1/2 trial • Oncology • Solid Tumor • CD40LG • MSLN
1 to 1
Of
1
Go to page
1